diazoxide has been researched along with Prader-Willi Syndrome in 3 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo." | 9.69 | Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. ( Abuzzahab, J; Angulo, M; Barrett, T; Bhatnagar, A; Bird, LM; Bridges, N; Butler, MG; Cowen, NM; Felner, EI; Gevers, E; Lah, M; Littlejohn, E; Mathew, V; Miller, JL; Obrynba, KS; Salehi, P; Shoemaker, AH; Stevenson, D; Yanovski, JA, 2023) |
| " The most common adverse events were peripheral edema and transient increases in glucose." | 6.90 | A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. ( Cowen, NM; Gold, JA; Kimonis, V; Surampalli, A; Wencel, M, 2019) |
| "In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo." | 5.69 | Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. ( Abuzzahab, J; Angulo, M; Barrett, T; Bhatnagar, A; Bird, LM; Bridges, N; Butler, MG; Cowen, NM; Felner, EI; Gevers, E; Lah, M; Littlejohn, E; Mathew, V; Miller, JL; Obrynba, KS; Salehi, P; Shoemaker, AH; Stevenson, D; Yanovski, JA, 2023) |
| "Treatment with diazoxide partially normalizes obesity in children and adults with PWS and in a PWS mouse model, demonstrating that the biological pathways impacted by diazoxide may be rational pharmacological targets in PWS and other disorders diseases associated with obesity." | 5.48 | Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome. ( Bischof, JM; Wevrick, R, 2018) |
| " The most common adverse events were peripheral edema and transient increases in glucose." | 2.90 | A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. ( Cowen, NM; Gold, JA; Kimonis, V; Surampalli, A; Wencel, M, 2019) |
| "Treatment with diazoxide partially normalizes obesity in children and adults with PWS and in a PWS mouse model, demonstrating that the biological pathways impacted by diazoxide may be rational pharmacological targets in PWS and other disorders diseases associated with obesity." | 1.48 | Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome. ( Bischof, JM; Wevrick, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, JL | 1 |
| Gevers, E | 1 |
| Bridges, N | 1 |
| Yanovski, JA | 1 |
| Salehi, P | 1 |
| Obrynba, KS | 1 |
| Felner, EI | 1 |
| Bird, LM | 1 |
| Shoemaker, AH | 1 |
| Angulo, M | 1 |
| Butler, MG | 1 |
| Stevenson, D | 1 |
| Abuzzahab, J | 1 |
| Barrett, T | 1 |
| Lah, M | 1 |
| Littlejohn, E | 1 |
| Mathew, V | 1 |
| Cowen, NM | 2 |
| Bhatnagar, A | 1 |
| Kimonis, V | 1 |
| Surampalli, A | 1 |
| Wencel, M | 1 |
| Gold, JA | 1 |
| Bischof, JM | 1 |
| Wevrick, R | 1 |
2 trials available for diazoxide and Prader-Willi Syndrome
| Article | Year |
|---|---|
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Topics: COVID-19; Diazoxide; Humans; Hyperphagia; Obesity; Prader-Willi Syndrome | 2023 |
A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Topics: Adolescent; Basal Metabolism; Body Composition; Child; Delayed-Action Preparations; Diazoxide; Doubl | 2019 |
1 other study available for diazoxide and Prader-Willi Syndrome
| Article | Year |
|---|---|
Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome.
Topics: Animals; Antigens, Neoplasm; Antihypertensive Agents; Body Fat Distribution; Diazoxide; Diet, High-F | 2018 |